FDA’s in-house review offers bleak assessment of Epizyme’s tazemetostat — but win or lose this cancer drug may still have a future

Epizyme will have to overcome a tough assessment from the FDA’s in-house review team for their cancer drug tazemetostat if they expect to make it to the market with an OK on epithelioid sarcoma. But they $EPZM may well have the agency’s oncology panel on their side, where there’s a built-in bias in favor of even marginal new drugs when it comes to offering physicians and patients another drug to choose from.